Publications by authors named "Edward Drea"

Claim this Profile
R
Rasburicase vs. allopurinol: mortality in hematological malignancies post anti-hyperuricemic therapy - real-world study.
Mitchell Stuart Cairo, Jack Ray Gallagher, Yvonne Barnes, Edward Drea, Christopher Clark

Support Care Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study.
Binod Dhakal, Mei-Jei Zhang, Linda J Burns, Xiaoying Tang, Christa Meyer, Edward J Drea

Haematologica· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective.
Alicia K Morgans, Thomas Hutson, Alice Kai Dan Guan, David Garcia, Anna Zhou, Edward Drea

BMC Health Serv Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Veterans Affairs Prostate Cancer Treatment Sequencing (VAPCaTS): A Real-World Evidence Study of Men with Metastatic Prostate Cancer.
Stephen J Freedland, Amanda M De Hoedt, Maral DerSarkissian, Rose Chang, Ambika Satija, Edward Drea

Urol Pract· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization.
Leslie A Andritsos, Ying Huang, Ivo Abraham, Keith Huff, Scott R Scrape, Edward Drea

Leuk Res· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Rachel P Riechelmann, Vichien Srimuninnimit, Roberto Bordonaro, Petr Kavan, Maria Di Bartolomeo, Edward Drea

Clin Colorectal Cancer· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.
William K Oh, Wendy Y Cheng, Raymond Miao, Francis Vekeman, Marjolaine Gauthier-Loiselle, Edward Drea

Urol Oncol· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis